{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T11:33:03Z","timestamp":1772191983068,"version":"3.50.1"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jneuroim.2025.578754","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T01:17:58Z","timestamp":1757467078000},"page":"578754","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Bortezomib for the treatment of anti-N-methyl-d-aspartate receptor encephalitis in a patient with psoriatic arthritis receiving adalimumab: A case report and literature review"],"prefix":"10.1016","volume":"409","author":[{"given":"Lohith","family":"Karigowda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kush","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jneuroim.2025.578754_bb0005","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.exphem.2016.05.005","article-title":"Bortezomib for the prevention and treatment of graftversushost disease after allogeneic hematopoietic stem cell transplantation","volume":"44","author":"AlHomsi","year":"2016","journal-title":"Exp. Hematol."},{"issue":"4","key":"10.1016\/j.jneuroim.2025.578754_bb0010","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1093\/ibd\/izaa302","article-title":"Autoimmune encephalitis during treatment with adalimumab: a case report in crohn\u2019s disease","volume":"27","author":"Alvarez","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578754_bb0015","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-225680","article-title":"Adalimumab induced acute myeloid leukaemia in a patient with Crohn\u2019s disease","volume":"12","author":"Alzahrani","year":"2019","journal-title":"BMJ Case Rep."},{"issue":"4","key":"10.1016\/j.jneuroim.2025.578754_bb0020","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.4049\/jimmunol.1501376","article-title":"Autoreactive CD19(+) CD20( ) plasma cells contribute to disease severity of experimental autoimmune encephalomyelitis","volume":"196","author":"Chen","year":"2016","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.jneuroim.2025.578754_bb0025","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/apt.12385","article-title":"Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration adverse event reporting system","volume":"38","author":"Deepak","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.jneuroim.2025.578754_bb0030","doi-asserted-by":"crossref","first-page":"e591","DOI":"10.1111\/jdv.16456","article-title":"Anti-N-methyl-d-aspartate receptor encephalitis during treatment with adalimumab for psoriasis","volume":"34","author":"Demarez","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"2016","key":"10.1016\/j.jneuroim.2025.578754_bb0035","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.nbd.2016.01.008","article-title":"CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy","volume":"88","author":"Foran","year":"2016","journal-title":"Neurobiol. Dis."},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578754_bb0040","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nrrheum.2011.1","article-title":"Longlived autoreactive plasma cells drive persistent autoimmune inflammation","volume":"7","author":"Hiepe","year":"2011","journal-title":"Nat. Rev. Rheumatol."},{"issue":"4","key":"10.1016\/j.jneuroim.2025.578754_bb0045","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.pedneo.2018.10.006","article-title":"Immunotherapy for antiNMDA receptor encephalitis: experience from a single center in Taiwan","volume":"60","author":"Kong","year":"2019","journal-title":"Pediatr. Neonatol."},{"key":"10.1016\/j.jneuroim.2025.578754_bb0050","series-title":"Clinical and Research Information on Drug-Induced Liver Injury [Internet]","author":"LiverTox","year":"2012"},{"issue":"5","key":"10.1016\/j.jneuroim.2025.578754_bb0055","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000001360","article-title":"Anti-N-methyl-D receptor encephalitis during long-term adalimumab therapy for Crohn\u2019s disease","volume":"11","author":"MacKay","year":"2024","journal-title":"ACG Case Rep. J."},{"key":"10.1016\/j.jneuroim.2025.578754_bb0060","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/s00415-020-10341-4","article-title":"NMDAR antibody encephalitis overlapping with CLIPPERS syndrome in a psoriasis patient on adalimumab","volume":"268","author":"Martin","year":"2021","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578754_bb0065","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/tcrm.2007.3.1.133","article-title":"Adalimumab in the treatment of arthritis","volume":"3","author":"Mease","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"issue":"5","key":"10.1016\/j.jneuroim.2025.578754_bb0070","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000476","article-title":"Anti\u2013NMDAR encephalitis in a patient with Crohn disease receiving adalimumab","volume":"5","author":"Noble","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.jneuroim.2025.578754_bb0075","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1517\/14740338.4.4.637","article-title":"Adalimumab: a review of side effects","volume":"4","author":"Scheinfeld","year":"2005","journal-title":"Expert Opin. Drug Saf."},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578754_bb0080","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for longterm outcome in patients with antiNMDA receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.jneuroim.2025.578754_bb0085","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1365-2125.2008.03263.x","article-title":"Adalimumab in dermatology","volume":"66","author":"Traczewski","year":"2008","journal-title":"Brit. J. Clin. Pharmaco."},{"key":"10.1016\/j.jneuroim.2025.578754_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fneur.2020.00188","article-title":"Early Bortezomib therapy for refractory anti-NMDA receptor encephalitis","volume":"11","author":"Turnbull","year":"2020","journal-title":"Front. Neurol."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572825002358?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572825002358?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T19:42:24Z","timestamp":1766086944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572825002358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":18,"alternative-id":["S0165572825002358"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578754","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bortezomib for the treatment of anti-N-methyl-d-aspartate receptor encephalitis in a patient with psoriatic arthritis receiving adalimumab: A case report and literature review","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578754","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"578754"}}